France Chronic Cough Therapeutics Market Analysis

France Chronic Cough Therapeutics Market Executive Summary

France Chronic Cough Therapeutics Market was valued at $173 Mn in 2022 and is estimated to reach $300 Mn in 2030, exhibiting a CAGR of 7.1% during the forecast period.

Chronic cough refers to a persistent cough lasting more than eight weeks, distinguishing it from acute coughs associated with short-term conditions. Unlike short-term coughs often linked to infections, chronic cough can indicate a more enduring underlying health problem. Respiratory conditions like asthma, chronic obstructive pulmonary disease (COPD), gastroesophageal reflux disease (GERD), postnasal drip, and certain medications commonly cause chronic cough. Identifying and addressing the root cause through a thorough medical assessment is essential for effective management. Chronic cough significantly impacts the quality of life, often requiring a comprehensive, multidisciplinary approach involving healthcare professionals such as pulmonologists, gastroenterologists, or ear, nose, and throat (ENT) specialists.

Chronic cough is a prevalent issue among adults, especially in the elderly population, with independent risk factors including current smoking, gastro-oesophageal reflux disease (GORD), asthma, and chronic obstructive pulmonary disease (COPD). Interventions such as smoking cessation and disease management can be beneficial for individuals at risk. The prevalence of chronic cough increases with age, peaking in the eighth decade, and is more common in women among those below 70 years. Over a 6-year follow-up, 439 new cases of chronic cough emerged, with an overall incidence rate of 11.6 per 1000 person-years, notably higher in men who are current smokers. Multivariable analysis identified current smoking, GORD, asthma, and COPD as significant risk factors. In Europe, approximately half of chronic cough cases lack a known cause, contributing to an overall prevalence of 12.7%, emphasizing the need for targeted interventions and exploration of potential causes for effective chronic cough management and prevention.

Merck's pharmaceutical product, gefapixant, has received approval in both the European Union and Japan for addressing chronic cough. The mechanism of action involves the inhibition of receptors responsible for nerve stimulation, consequently alleviating the urge to cough. Administered twice daily, the gefapixant underwent comprehensive evaluation in two late-stage trials. The findings revealed that a higher dosage demonstrated a statistically significant reduction in the average number of coughs per hour over a 24-hour period when compared to a placebo. This approval underscores gefapixant's efficacy in managing chronic cough, marking a significant development in the field of respiratory therapeutics.

Market Dynamics

Market Growth Drivers

Increasing Prevalence of Respiratory Conditions: The rising incidence of respiratory disorders, such as asthma, chronic obstructive pulmonary disease (COPD), and other respiratory infections, contributes to the demand for chronic cough therapeutics in France. As the prevalence of these conditions grows, there is a parallel increase in the need for effective treatments, driving the market forward.

Advancements in Medical Research and Technology: Ongoing advancements in medical research and technology play a crucial role in the development of innovative and more targeted chronic cough therapeutics. The integration of cutting-edge technologies and a deeper understanding of the underlying mechanisms of chronic cough can lead to the creation of more efficacious treatments, fostering market growth.

Government Initiatives and Healthcare Policies: Supportive healthcare policies and government initiatives aimed at improving respiratory health and patient outcomes contribute to market growth. Policies that emphasize early diagnosis, treatment accessibility, and affordability of medications for chronic cough can positively impact the market by fostering a conducive environment for the development and adoption of therapeutics.

Market Restraints

Limited Awareness and Diagnosis: A constraint for the chronic cough therapeutics market in France is the limited awareness and delayed diagnosis of chronic cough among the population. This may lead to underutilization of available treatments and hinder market growth.

Reimbursement Challenges: Issues related to reimbursement policies and coverage for chronic cough therapeutics may pose a restraint. Limited reimbursement options can affect patient access to expensive medications and impact the market dynamics.

Regulatory Hurdles: Complex regulatory processes and stringent approval requirements in France can slow down the introduction of new chronic cough therapeutics. Compliance with regulatory standards may be challenging, creating obstacles for pharmaceutical companies entering the market and launching new products.

Healthcare Policies and Regulatory Landscape

In France, healthcare policies and the regulatory landscape governing therapeutic drugs are overseen by entities such as the Haute Autorité de Santé (HAS), which assesses the effectiveness and cost-effectiveness of healthcare interventions, and the French National Agency for Medicines and Health Products Safety (ANSM), responsible for regulating and overseeing the safety of medicines. The Pricing and Reimbursement Committee (CEPS) engages in negotiations regarding drug prices to ensure economic sustainability, while the Transparency Commission, operating under HAS, assesses the therapeutic value of drugs and provides recommendations for reimbursement. The French Social Security System plays a pivotal role in financing healthcare, including the reimbursement of drugs. Additionally, adherence to European standards is imperative, necessitating approval from the European Medicines Agency (EMA) for marketing authorization. This comprehensive framework is designed to maintain rigorous standards for drug safety, efficacy, and affordability within the context of the French healthcare system.

Competitive Landscape

Key Players

• Boiron
• AstraZeneca
• GlaxoSmithKline
• Sanofi
• Pfizer
• Merck
• Johnson & Johnson
• Novartis
• Teva Pharmaceutical Industries
• Pierre Fabre Laboratories